Subscribe today to receive notice of our latest blogs, articles, podcasts, and more.
Clinical Connection
Thought leadership on the clinical impact on workers' compensation and auto no-fault.
Recent blog posts
|
May 08, 2023 · Clinical Team
The U.S. Food and Drug Administration (FDA) announced that Teva Pharmaceuticals USA voluntarily recalled specific lots of various strengths of fentanyl buccal tablets at the consumer level. Read more... |
|
|
May 02, 2023 · Clinical Team
On March 29, 2023, the U.S. Food and Drug Administration (FDA) approved Narcan® (naloxone hydrochloride) 4 mg Nasal Spray for over-the-counter (OTC), nonprescription, use. Read more... |
|
|
May 01, 2023 · Clinical Team
Akorn Operating Company LLC filed Chapter 7 bankruptcy and the company has ceased all operations, including the discontinuation of the quality activities of these marketed drug products. Read more... |
|
|
April 20, 2023 · Clinical Team
On April 21, 2023, the ODG Drug Formulary (Appendix A) status will change for several medications within the topical analgesic and nonsteroidal anti-inflammatory (NSAID) classes. Read more... |
|
|
April 06, 2023 · Clinical Team
Our Brand–Generic Pipeline lists new medications approved by the U.S. FDA and first-time generics or brand alternatives that potentially may be prescribed for the treatment of a workers’ compensation or auto injury. The Brand–Generic Pipeline for Q1 2023 is now available -- read it here. Read more... |
|
|
October 20, 2022 · Clinical Team
When it comes to unused prescription medications, the Drug Enforcement Agency (DEA) encourages everyone to “Keep them safe. Clean them out. Take them back.” They enforce this motto by sponsoring National Prescription Drug Take Back Days. Read more... |
|
|
July 14, 2022 · Clinical Team
Effective June 30, 2022, Zelnorm 6 mg tablet will no longer be produced and marketed in the United States, as announced by its manufacturer, Alfasigma USA, Inc. Read more... |
|
July 06, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) approved Quviviq (daridorexant) 25 mg and 50 mg tablets on January 10, 2022. Manufactured by Idorsia Pharmaceuticals US Inc., this sedative/hypnotic is indicated for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. Read more... |
Page 1 of 7
Additional Resources
Case Studies
Comorbidity series
Zantac/ranitidine recall updates
Continuing Education
Thought Leadership
